ClinicalTrials.Veeva

Menu

Hippocampal Memory Circuits in Delusions

NYU Langone Health logo

NYU Langone Health

Status

Completed

Conditions

Psychosis

Treatments

Diagnostic Test: Pattern Separation Paradigm
Diagnostic Test: Encoding Plasticity Paradigm
Diagnostic Test: Sequential Associative Mismatch Paradigm

Study type

Observational

Funder types

Other
NIH

Identifiers

NCT03822910
18-00656

Details and patient eligibility

About

This study will investigate dentate gyrus (DG) and hippocampal CA3 sub field function, using the pattern separation paradigm, as reflected by the difference in brain activation in response to same-as-previously- seen (OLD) vs. similar-to-previously-seen (SIM) objects in first episode psychosis (FEP) subjects before and after anti psychotic treatment and in matched healthy controls (HC). The current study uses three novel high-resolution task-based and post-encoding resting fMRI measures to probe hippocampal circuitry in delusions. It will also study CA1 function, using a sequential associative mismatch paradigm, as reflected by activation of CA1 in response to mismatching information compared to memory of that stimulus in FEP subjects before and after antipsychotic treatment and in matched HC. Finally, this study will evaluate plasticity of hippocampal intrinsic functional connectivity (IFC) in response to memory consolidation, using an encoding-plasticity paradigm, in FEP subjects before and after anti psychotic treatment and in matched HC. For each of the three imaging projects, a total of 50 FEP subjects and 50 matched healthy controls (HC) will be studied; hence, 300 subjects will be studied over 5 years. Within each paradigm, medication-naive FEP subjects will be studied at baseline and 8 weeks after starting anti psychotic medication. HC participants will be studied at baseline and 8 weeks later but will not receive any treatment.

Enrollment

212 patients

Sex

All

Ages

16 to 35 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Males and females 16 to 35 years of age, inclusive, at the time of informed consent
  • Right-handed
  • Must have experienced a first episode of non-affective psychosis over the past five years
  • Must exhibit a persistence of delusions for at least 4 days per week for at least 4 weeks in the absence of psychotomimetic substance use or other potential organic etiologies, including epilepsy or significant head trauma.
  • Must score at least a 2 (mild to moderate) on the "Amount of preoccupation with delusions" and "Conviction" items on the Psychotic Symptom Rating Scale (PSYRATS).

Exclusion criteria

  • Diagnosis of major mood disorder or other Axis I disorder other than Schizophrenia, Schizoaffective Disorder or Schizophreniform Disorder.
  • Significant medical or neurological illness by history or physical exam including seizure disorder, history of loss of consciousness related to head trauma or developmental disorder including mental retardation.
  • Metal implants, pacemaker, or other metal in the body or medicinal patch.
  • History of claustrophobia.
  • Currently taking any anti psychotic medication (within 4 weeks).

Trial design

212 participants in 2 patient groups

Healthy Controls
Description:
Matched Healthy Controls
Treatment:
Diagnostic Test: Sequential Associative Mismatch Paradigm
Diagnostic Test: Encoding Plasticity Paradigm
Diagnostic Test: Pattern Separation Paradigm
Firt Episode Psychosis (FEP)
Description:
subjects before and after antipsychotic treatment
Treatment:
Diagnostic Test: Sequential Associative Mismatch Paradigm
Diagnostic Test: Encoding Plasticity Paradigm
Diagnostic Test: Pattern Separation Paradigm

Trial contacts and locations

3

Loading...

Central trial contact

Gillian Capichioni

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems